197 related articles for article (PubMed ID: 31009361)
1. Extent of Ischemic Brain Injury After Thrombotic Stroke Is Independent of the NLRP3 (NACHT, LRR and PYD Domains-Containing Protein 3) Inflammasome.
Lemarchand E; Barrington J; Chenery A; Haley M; Coutts G; Allen JE; Allan SM; Brough D
Stroke; 2019 May; 50(5):1232-1239. PubMed ID: 31009361
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the NLRP3-inflammasome as a potential approach for neuroprotection after stroke.
Ismael S; Zhao L; Nasoohi S; Ishrat T
Sci Rep; 2018 Apr; 8(1):5971. PubMed ID: 29654318
[TBL] [Abstract][Full Text] [Related]
3. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.
Vande Walle L; Stowe IB; Šácha P; Lee BL; Demon D; Fossoul A; Van Hauwermeiren F; Saavedra PHV; Šimon P; Šubrt V; Kostka L; Stivala CE; Pham VC; Staben ST; Yamazoe S; Konvalinka J; Kayagaki N; Lamkanfi M
PLoS Biol; 2019 Sep; 17(9):e3000354. PubMed ID: 31525186
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the NLRP3 inflammasome reduces brain edema and regulates the distribution of aquaporin-4 after cerebral ischaemia-reperfusion.
Wang H; Chen H; Jin J; Liu Q; Zhong D; Li G
Life Sci; 2020 Jun; 251():117638. PubMed ID: 32251636
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation.
Primiano MJ; Lefker BA; Bowman MR; Bree AG; Hubeau C; Bonin PD; Mangan M; Dower K; Monks BG; Cushing L; Wang S; Guzova J; Jiao A; Lin LL; Latz E; Hepworth D; Hall JP
J Immunol; 2016 Sep; 197(6):2421-33. PubMed ID: 27521339
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of NLRP3 Inflammasome Ameliorates Cerebral Ischemia-Reperfusion Injury in Diabetic Mice.
Hong P; Li FX; Gu RN; Fang YY; Lai LY; Wang YW; Tao T; Xu SY; You ZJ; Zhang HF
Neural Plast; 2018; 2018():9163521. PubMed ID: 29853850
[TBL] [Abstract][Full Text] [Related]
7. NLRP3 inflammasome activates interleukin-23/interleukin-17 axis during ischaemia-reperfusion injury in cerebral ischaemia in mice.
Wang H; Zhong D; Chen H; Jin J; Liu Q; Li G
Life Sci; 2019 Jun; 227():101-113. PubMed ID: 31002919
[TBL] [Abstract][Full Text] [Related]
8. Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury.
Xu X; Yin D; Ren H; Gao W; Li F; Sun D; Wu Y; Zhou S; Lyu L; Yang M; Xiong J; Han L; Jiang R; Zhang J
Neurobiol Dis; 2018 Sep; 117():15-27. PubMed ID: 29859317
[TBL] [Abstract][Full Text] [Related]
9. Nlrp3 Inflammasome Inhibitor MCC950 Ameliorates Obliterative Bronchiolitis by Inhibiting Th1/Th17 Response and Promoting Treg Response After Orthotopic Tracheal Transplantation in Mice.
Xu KY; Tong S; Wu CY; Ding XC; Chen JL; Ming Y; Wang SH
Transplantation; 2020 Jun; 104(6):e151-e163. PubMed ID: 32108749
[TBL] [Abstract][Full Text] [Related]
10. The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice.
Qu J; Yuan Z; Wang G; Wang X; Li K
Int Immunopharmacol; 2019 May; 70():147-155. PubMed ID: 30802677
[TBL] [Abstract][Full Text] [Related]
11. The NLRP3 inflammasome modulates glycolysis by increasing PFKFB3 in an IL-1β-dependent manner in macrophages.
Finucane OM; Sugrue J; Rubio-Araiz A; Guillot-Sestier MV; Lynch MA
Sci Rep; 2019 Mar; 9(1):4034. PubMed ID: 30858427
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death.
Matsuoka T; Yoshimatsu G; Sakata N; Kawakami R; Tanaka T; Yamada T; Yoshida Y; Hasegawa S; Kodama S
Sci Rep; 2020 Oct; 10(1):17920. PubMed ID: 33087823
[TBL] [Abstract][Full Text] [Related]
13. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting the NLRP3 inflammasome with MCC950 ameliorates retinal neovascularization and leakage by reversing the IL-1β/IL-18 activation pattern in an oxygen-induced ischemic retinopathy mouse model.
Sui A; Chen X; Shen J; Demetriades AM; Yao Y; Yao Y; Zhu Y; Shen X; Xie B
Cell Death Dis; 2020 Oct; 11(10):901. PubMed ID: 33093455
[TBL] [Abstract][Full Text] [Related]
15. MCC950 attenuated early brain injury by suppressing NLRP3 inflammasome after experimental SAH in rats.
Luo Y; Lu J; Ruan W; Guo X; Chen S
Brain Res Bull; 2019 Mar; 146():320-326. PubMed ID: 30716395
[TBL] [Abstract][Full Text] [Related]
16. NLRP3 inflammasome inhibition attenuates subacute neurotoxicity induced by acrylamide in vitro and in vivo.
Sui X; Yang J; Zhang G; Yuan X; Li W; Long J; Luo Y; Li Y; Wang Y
Toxicology; 2020 Feb; 432():152392. PubMed ID: 32014472
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation.
Yao C; Veleva T; Scott L; Cao S; Li L; Chen G; Jeyabal P; Pan X; Alsina KM; Abu-Taha I; Ghezelbash S; Reynolds CL; Shen YH; LeMaire SA; Schmitz W; Müller FU; El-Armouche A; Tony Eissa N; Beeton C; Nattel S; Wehrens XHT; Dobrev D; Li N
Circulation; 2018 Nov; 138(20):2227-2242. PubMed ID: 29802206
[TBL] [Abstract][Full Text] [Related]
18. NLRP3 inflammasome inhibition attenuates cisplatin-induced renal fibrosis by decreasing oxidative stress and inflammation.
Li S; Lin Q; Shao X; Mou S; Gu L; Wang L; Zhang Z; Shen J; Zhou Y; Qi C; Jin H; Pang H; Ni Z
Exp Cell Res; 2019 Oct; 383(1):111488. PubMed ID: 31276670
[TBL] [Abstract][Full Text] [Related]
19. NLRP3 inflammasome inhibition with MCC950 improves diabetes-mediated cognitive impairment and vasoneuronal remodeling after ischemia.
Ward R; Li W; Abdul Y; Jackson L; Dong G; Jamil S; Filosa J; Fagan SC; Ergul A
Pharmacol Res; 2019 Apr; 142():237-250. PubMed ID: 30818045
[TBL] [Abstract][Full Text] [Related]
20. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition.
Coll RC; Hill JR; Day CJ; Zamoshnikova A; Boucher D; Massey NL; Chitty JL; Fraser JA; Jennings MP; Robertson AAB; Schroder K
Nat Chem Biol; 2019 Jun; 15(6):556-559. PubMed ID: 31086327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
